

**Unaudited Financial Results (Provisional)
for the Quarter ended 30th June, 2007**

(Rs. in Lac)

Particulars	For the quarter ended		Year ended
	30.06.2007	30.06.2006	31.03.2007
	(Unaudited)	(Unaudited)	(Audited)
Turnover	23,472	23,683	83,979
Less: Excise Duty	129	344	824
Income from Operations	23,343	23,339	83,155
Other Income	882	840	2,996
Total Income	24,225	24,179	86,151
(Increase) / Decrease in Stocks	(539)	2,773	1,176
Consumption of Materials & bought outs	11,780	7,997	37,419
Manufacturing Expenses	483	401	2,198
Personnel Expenses	1,843	1,397	7,880
Others	2,742	2,288	11,494
Total Expenditure	16,309	14,856	60,167
Interest	97	779	1,522
Gross Profit after Interest but before Depreciation & Tax	7,819	8,544	24,462
Depreciation	918	694	3,552
Profit before Tax	6,901	7,850	20,910
Provision for taxation	1,885	2,532	4,639
Fringe Benefits Tax	52	60	220
Deferred Tax Liabilities/ (Assets)	239	282	1,370
Net Profit	4,725	4,976	14,681
Paid-up Share Capital			
Equity (Face Value Re.1/- per Share)	658	571	658
Preference (Face Value Rs.10/- per Share)	-	9,043	-
Reserves & Surplus			53,251
E.P.S. (Rs.)			23.71
- Basic	7.19	8.51	
- Diluted	6.63	6.88	21.73
Aggregate of Public Shareholding			
Number of Shares	22,235,652	13,601,610	22,207,664
Percentage of holding	33.76	23.77	33.73

Unaudited Segment wise Revenue, Results and Capital employed			
Particulars	For the quarter ended		Year ended
	30.06.2007	30.06.2006	31.03.2007
	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue			
A. Vaccines	18,430	19,399	66,387
B. Formulations	5,011	3,936	17,002
C. Research & Development	-	30	78
Gross Sales/ Income from Operations	23,441	23,365	83,467
Less : Inter Segment Revenue	-	-	-
Net Sales/ Income from Operations	23,441	23,365	83,467
Segment Results			
A. Vaccines	7,934	9,191	28,285
B. Formulations	811	634	2,849
C. Research & Development	(1,185)	(871)	(4,972)
Total	7,560	8,954	26,162
Less : Interest & Financial Charges	114	786	1,424
Unallocated Expenditure net of unallocated Income	545	318	3,828
Total Profit Before Tax	6,901	7,850	20,910
Capital Employed			
A. Vaccines	36,601	26,076	29,930
B. Formulations	16,319	16,194	15,100
C. Research & Development	12,514	8,347	11,257
Capital employed in Segments	65,434	50,617	56,287
Add: Unallocable Assets Less Liabilities	(6,711)	(20,704)	(2,377)
Total Capital employed	58,723	29,913	53,910

Notes:

- The above financial results were reviewed by the Audit Committee of the Board and taken on record by the Board of Directors at their meetings held on 23rd July, 2007 & 24th July, 2007, respectively and are subject to limited review by Auditors of the Company.
- During the quarter, the Company's Turnover from Formulations segment grew by 27% and the Vaccines Turnover to Joint Venture Company viz. Chiron Panacea Vaccines Pvt. Ltd. also grew by 54%. The Company's monthly ORG IMS SSA ranking for June, 07 has improved to 47th from 49th.
- During the quarter, the Company launched **Fitliv Dia** Nutritional Biscuit (Nutritional Supplement for diabetic patients), **Glizid M OD 60mg** Tablet (for Type 2 Diabetes), **Lower CVD** Capsule (for cardiac prevention), **Lower TG** Tablet (for Dyslipidemia), **Pangraf 2.0 Mg** Capsule (a Prophylaxis in Organ Transplant), **Cefmentin 100 & 50 DT** Tablets (for Respiratory, GI & Urinary Tract Infections), **Fego HF** Tablet (Nimesulide + Paracetamol), **Levo MDR** tablet (for MDR TB), **Zomont AL** Tablet (for Allergic Rhinitis), **Zomont-Theo 200 mg** Tablet (for Acute Pain) and **Softdiclo Acute** Capsule (for acute pain).
- The Company's Register of Members and Share Transfer Books shall remain closed from Tuesday, 25th September, 2007 to Saturday, 29th September, 2007 (both days inclusive) for ascertaining the entitlement to receive dividend, if any, declared by the Shareholders in the ensuing Annual General Meeting scheduled to be held on Saturday, 29th September, 2007.
- Status of Investors' complaints [in nos.] during the quarter, pursuant to clause 41 of listing agreement: Opening [0]; Received [4]; Disposed [4]; Closing [0].
- The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary.

New Delhi
July 24, 2007

For and on behalf of the Board
Soshil Kumar Jain
Chairman

Panacea Biotec Ltd.

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab

Website : <http://www.panacea-biotec.com>